"Why is keeping the product sterile so expensive? Because you've got very expensive cleanrooms and the most expensive thing is the people working in the cleanrooms. So, you have to close the system, you have to automate. You want to put the process in a box and the people outside," Caplan said. "Less people in sterile cleanrooms, closer to the patient, closed loop production -- all these reduce the cost of the product and make it affordable."

Orgenesis has partnered with hospitals to deploy its automated, closed, and flexible Orgenesis Mobile Production Units and Labs (OMPULs) for the development of CGTs. OMPULs can be rapidly deployed as a standardized industrial cleanroom alternative at or near the point of care.

Watch the video below to learn more.

ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT)...

ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...

ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...

ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net...

ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...